Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561049 | 0.95 | PTGER4 (0.94) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3567548 | 0.95 | PTGER4 (0.94) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3561068 | 0.95 | PTGER4 (0.90) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3567596 | 0.95 | PTGER4 (0.90) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3963568 | 0.94 | PTGER4 (0.94) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3961249 | 0.94 | PTGER4 (0.94) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3961221 | 0.93 | PTGER4 (0.87) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3566669 | 0.92 | PTGER4 (0.87) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3566292 | 0.92 | PTGER4 (0.87) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL2299905 | 0.92 | PTGER4 (1.00) | PTGER4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1886993-B1 | BENZO[F]ISOINDOLE DERIVATIVES WITH AFFINITY TO THE EP4 RECEPTOR | GLAXO GROUP LTD (GB) | 2013-09-18 | — | — | EP | claimed |
| US-7732622-B2 | Naphthalene derivatives | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | claimed |
| US-20080234358-A1 | E-series of prostaglandin (EP) receptors; [[4-(4,9-dipropoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl) phenyl]acetic acid | CONGREVE MILES STUART | 2008-09-25 | — | — | US | claimed |
| EP-1886993-A1 | BENZO[F]ISOINDOLE DERIVATIVES WITH AFFINITY TO THE EP4 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-02-13 | — | — | EP | claimed |
| EP-1442744-B1 | EP4 receptor ligand and use against neuropathic pain, colon cancer, HIV and migrane | GLAXO GROUP LTD (GB) | 2006-12-20 | — | — | EP | claimed |
| US-20050096368-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2005-05-05 | — | — | US | claimed |
| US-20050080257-A1 | Benzo'fisoindole derivatives with affinity to the ep4 receptor | GLAXO GROUP LIMITED (GB) | 2005-04-14 | — | — | US | claimed |
| US-6861441-B1 | Use of EP4 receptor ligands in the treatment of neuropathic pain and colon cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-01 | — | — | US | claimed |
| EP-1442744-A2 | Use of EP4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer | GLAXO GROUP LIMITED (GB) | 2004-08-04 | — | — | EP | claimed |
| WO-2002047669-A1 | USE OF EP4 RECEPTOR AGONISTS FOR TREATING NEUROPATHIC PAIN | GLAXO GROUP LIMITED (GB) | 2002-06-20 | — | — | WO | claimed |
| EP-1886993-B1 | BENZO[F]ISOINDOLE DERIVATIVES WITH AFFINITY TO THE EP4 RECEPTOR | GLAXO GROUP LTD (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-8252833-B2 | Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-08-28 | — | — | US | disclosed |
| EP-1979316-B1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2012-07-11 | — | — | EP | disclosed |
| EP-2457897-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| WO-2002050033-A1 | BENZO(F) ISOINDOL DERIVATIVES AND THEIR USE AS EP4 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| WO-2002047669-A1 | USE OF EP4 RECEPTOR AGONISTS FOR TREATING NEUROPATHIC PAIN | GLAXO GROUP LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
| WO-2002047669-A1 | USE OF EP4 RECEPTOR AGONISTS FOR TREATING NEUROPATHIC PAIN | GLAXO GROUP LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
| EP-1202730-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF NEUROPATHIC PAIN AND COLON CANCER | GLAXO GROUP LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010426-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF NEUROPATHIC PAIN AND COLON CANCER | GLAXO GROUP LIMITED (GB) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885CYP1A2 284/4885CYP2D6 447/4885 |
| US-20050096368-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | HRH4, LTC4S, HCAR3 | PTGER4 25/4885CYP1A2 947/4885CYP2D6 855/4885 |
| US-20050080257-A1 | Benzo'fisoindole derivatives with affinity to the ep4 receptor | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885CYP1A2 532/4885CYP2D6 467/4885 |
| US-20080234358-A1 | E-series of prostaglandin (EP) receptors; [[4-(4,9-dipropoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl) phenyl]acetic acid | PTGER3, OPRL1, PTGER1 | PTGER4 21/4885CYP1A2 567/4885CYP2D6 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.